Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2022.859905 http://scihub22266oqcxt.onion/10.3389/fimmu.2022.859905 35693819!9175637!35693819     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2022 ; 13 (ä): 859905 Nephropedia Template TP {{tp|p=35693819|t=2022. SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World s Population |pdf=|usr=}}{{35693819}} gab.com Text SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World s Population JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=35693819 #FOAvip Fifty ~20-amino acid (aa)-long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial B-21 and another 53 common ones, plus some new ones derived from the virus' main genetic variants for complementary trial C-21. Peptide selection was based on tremendous SARS-CoV-2 genetic variability for analysing them concerning vast human immunogenetic polymorphism for developing the first supramutational, Colombian SARS-protection (SM-COLSARSPROT), peptide mixture. Specific physicochemical rules were followed, i.e., aa predilection for polyproline type II left-handed (PPII(L)) formation, replacing beta-branched, aromatic aa, short-chain backbone H-bond-forming residues, pi-pi interactions (n-->pi* and pi-CH), aa interaction with pi systems, and molecular fragments able to interact with them, disrupting PPII(L) propensity formation. All these modified structures had PPII(L) formation propensity to enable target peptide interaction with human leukocyte antigen-DRbeta1* (HLA-DRbeta1*) molecules to mediate antigen presentation and induce an appropriate immune response. Such modified peptides were designed for human use; however, they induced high antibody titres against S, M, and E parental mutant peptides and neutralising antibodies when suitably modified and chemically synthesised for immunising 61 major histocompatibility complex class II (MHCII) DNA genotyped Aotus monkeys (matched with their corresponding HLA-DRbeta1* molecules), predicted to cover 77.5% to 83.1% of the world's population. Such chemically synthesised peptide mixture represents an extremely pure, stable, reliable, and cheap vaccine for COVID-19 pandemic control, providing a new approach for a logical, rational, and soundly established methodology for other vaccine development. Twit Text FOAVip SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World s Population ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=35693819 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35693819 #FOAvip English Wikipedia <ref>{{Cite pmid|35693819}}</ref> SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World s Population #MMPMID35693819 Patarroyo MA; Patarroyo ME; Pabon L; Alba MP; Bermudez A; Rugeles MT; Diaz-Arevalo D; Zapata-Builes W; Zapata MI; Reyes C; Suarez CF; Agudelo W; Lopez C; Aza-Conde J; Melo M; Escamilla L; Oviedo J; Guzman F; Silva Y; Forero M; Florez-Alvarez L; Aguilar-Jimenez W; Moreno-Vranich A; Garry J; Avendano C Front Immunol 2022[]; 13 (ä): 859905 PMID35693819show ga Fifty ~20-amino acid (aa)-long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial B-21 and another 53 common ones, plus some new ones derived from the virus' main genetic variants for complementary trial C-21. Peptide selection was based on tremendous SARS-CoV-2 genetic variability for analysing them concerning vast human immunogenetic polymorphism for developing the first supramutational, Colombian SARS-protection (SM-COLSARSPROT), peptide mixture. Specific physicochemical rules were followed, i.e., aa predilection for polyproline type II left-handed (PPII(L)) formation, replacing beta-branched, aromatic aa, short-chain backbone H-bond-forming residues, pi-pi interactions (n-->pi* and pi-CH), aa interaction with pi systems, and molecular fragments able to interact with them, disrupting PPII(L) propensity formation. All these modified structures had PPII(L) formation propensity to enable target peptide interaction with human leukocyte antigen-DRbeta1* (HLA-DRbeta1*) molecules to mediate antigen presentation and induce an appropriate immune response. Such modified peptides were designed for human use; however, they induced high antibody titres against S, M, and E parental mutant peptides and neutralising antibodies when suitably modified and chemically synthesised for immunising 61 major histocompatibility complex class II (MHCII) DNA genotyped Aotus monkeys (matched with their corresponding HLA-DRbeta1* molecules), predicted to cover 77.5% to 83.1% of the world's population. Such chemically synthesised peptide mixture represents an extremely pure, stable, reliable, and cheap vaccine for COVID-19 pandemic control, providing a new approach for a logical, rational, and soundly established methodology for other vaccine development. |*COVID-19[MESH] |*Malaria Vaccines[MESH] |Amino Acid Sequence[MESH] |COVID-19 Vaccines[MESH] |Histocompatibility Antigens Class II/genetics[MESH] |Humans[MESH] |Peptides[MESH]SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides (epmc).pdf DeepDyve Pubget Overpricing